Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers

doi:10.4330/wjc.v12.i8.373

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (15350)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

1076

WORD

256

HTML

11807

Figures (1-5)

472

Tables (1-2)

205

Sum=13816

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

606

Download

928

Sum=1534

Aug 26, 2020 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (59)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Cardiol. Aug 26, 2020; 12(8): 373-408
Published online Aug 26, 2020. doi: 10.4330/wjc.v12.i8.373

Full Size Figure Download Figure

Figure 3 Physiological and pathophysiological implications of neuropeptide Y and galanin with respect to cardiovascular system. Ach: Acetylcholine; ERP: Effective refractory period; HF: Heart failure; IRI: Ischemia-reperfusion injury; LV: Left ventricular; MI: Myocardial infarction; NPY: Neuropeptide Y; STEMI: ST-elevation myocardial infarction; VIP: Vasoactive intestinal peptide.

Citation: Borovac JA, D'Amario D, Bozic J, Glavas D. Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers. World J Cardiol 2020; 12(8): 373-408
URL: https://www.wjgnet.com/1949-8462/full/v12/i8/373.htm
DOI: https://dx.doi.org/10.4330/wjc.v12.i8.373